Sandoz Miktosan 0.4 mg

Miktosan is a brand of tamsulosin hydrochloride, primarily used for treating symptoms of an enlarged prostate. The brand is managed by Sandoz, a global leader in generic and biosimilar pharmaceuticals. Originally a Swiss brand rooted in the history of Kern & Sandoz (1886), it spent many decades as part of the Novartis group.

Following a strategic spin-off in late 2023, Sandoz became an independent, publicly-traded company. While the brand has Swiss origins, its manufacturing footprint is global, with significant production facilities located across Europe (notably Germany, Austria, and Slovenia) as well as other international sites. In the Danish market, it is distributed through regional pharmaceutical supply chains as a prescription medication.